Praluent access in Pakistan: the DRAP named-patient pathway
How families and patients in Pakistan obtain Praluent (alirocumab) for familial hypercholesterolemia and atherosclerotic cardiovascular disease through the Drug Regulatory Authority of Pakistan Personal Use Import framework.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Ask about Praluent in Pakistan
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Praluent is the brand name for alirocumab, a fully human IgG1 monoclonal antibody co-developed by Regeneron Pharmaceuticals and Sanofi that binds PCSK9 and raises the density of LDL receptors on hepatocytes, lowering circulating LDL cholesterol. The US FDA first approved Praluent in July 2015 as the first PCSK9 inhibitor on the US market, expanded the label in April 2019 to include cardiovascular risk reduction after acute coronary syndrome based on the ODYSSEY OUTCOMES trial, and has subsequently extended the indication to homozygous familial hypercholesterolemia (HoFH) as an adjunct to other LDL-lowering therapies. For Pakistani families whose local pharmacy stocks no PCSK9 inhibitor, or whose treating cardiologist prefers Praluent specifically, the DRAP Special Permission for Personal Use Import is the operative pathway.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
Why patients in Pakistan reach for Praluent through NPP
Pakistan's specialty pharmaceutical market is cash-pay dominant for advanced therapies, and the PCSK9 inhibitor class sits squarely in that segment. Praluent's registration status in Pakistan is uneven, and even where the SFDA or MOHAP-registered presentations cross over via regional agents, on-shelf availability at the pharmacy a Pakistani family actually walks into is inconsistent. Three structural patterns drive Praluent demand through the named-patient route. First, stocking variability. PCSK9 inhibitors in Pakistan are concentrated in tertiary cardiology and lipid-clinic settings in Karachi, Lahore, and Islamabad. A patient referred from Faisalabad, Multan, Peshawar, or Quetta to start PCSK9 therapy may find that even the major Karachi or Lahore pharmacy does not carry Praluent in stock, with a multi-week reorder lead time.
Second, the FH cohort, particularly the pediatric tail. For these families, the question is not Praluent versus an alternative; it is PCSK9 therapy or untreated cardiovascular risk in a child. Third, patient and prescriber preference between Praluent and Repatha (evolocumab). Where Repatha is the locally stocked PCSK9 inhibitor, a cardiologist or patient who responded to Praluent in prior treatment or who prefers the 300 mg every-4-weeks dosing option may want to source Praluent specifically. Reserve Meds is not the filer of choice between the two; we coordinate on the prescription written.
The DRAP Personal Use Import pathway for Praluent
The Drug Regulatory Authority of Pakistan (DRAP), established in 2012 under the DRAP Act and reporting to the Federal Ministry of National Health Services, Regulations and Coordination, regulates the import of medicines through its Quality Assurance and Laboratory Testing (QA<) Division's Import and Export Section. For unregistered or stocked-but-unavailable medicines required by a specific patient, DRAP issues a Special Permission, commonly referred to as the No Objection Certificate (NOC) for Personal Use Import. Applications are filed through DRAP's Online Import and Export System (OIES) portal, an electronic application channel that lets the applicant, the hospital pharmacy, and DRAP communicate digitally.
For Praluent the clinical justification angle is lipid- and indication-specific. A complete application typically includes:
- A clinical justification letter on hospital letterhead from the treating cardiologist, lipidologist, or internal medicine physician with lipid-clinic experience, documenting the FDA-approved on-label indication: adult HeFH, adult HoFH (as adjunct), adult ASCVD requiring additional LDL-C lowering, or adult cardiovascular risk reduction after acute coronary syndrome
- Lipid-panel results documenting LDL-C trajectory on maximally tolerated statin therapy with or without ezetimibe.
- A recent prescription specifying brand name (Praluent), generic name (alirocumab), presentation (75 mg pre-filled pen, 150 mg pre-filled pen, or 300 mg presentation for monthly dosing), quantity, and dosing schedule
- The treating physician's PMDC license verification
- The patient identifier: CNIC for adult patients, B-Form for minors, passport for foreign nationals receiving treatment in Pakistan
- Product details: brand name, generic name (INN), manufacturer Regeneron Pharmaceuticals (Tarrytown, NY), strength, dosage form, quantity, and batch number where available
- The destination dispensing facility license (hospital pharmacy license for institutional dispensing)
- A manufacturer or authorized distributor letter confirming the product is genuine and was sourced through the legitimate US specialty pharmacy supply chain
- The chain-of-custody plan from the US source through international shipment to the dispensing facility, including 2 to 8 degree Celsius cold-chain handling with continuous temperature monitoring
We give you a written timeline estimate for your case before you commit. Reserve Meds plans on the longer end and treats any faster turnaround as upside.
Where Praluent gets dispensed in Pakistan
Praluent is a refrigerated biologic that the patient or caregiver self-administers by subcutaneous injection after physician or nurse training. The dispensing facilities in Pakistan with the import pharmacy infrastructure, PMDC-licensed cardiology and lipidology rosters, and cold-chain capability for a 2 to 8 degree Celsius biologic are concentrated in Karachi, Lahore, and Islamabad.
Smaller clinics outside Karachi, Lahore, and Islamabad typically partner with a DRAP-licensed specialty importer based in Karachi or Lahore that handles the OIES filing, FBR Customs clearance, and chain-of-custody documentation, and arranges dispensing through one of the major-city tertiary facilities.
Real cost picture for Praluent in Pakistan
Medicine price: quote on request. You get a written quote for your case before you commit.
Medicine price: quote on request. You get a written quote for your case before you commit. On the insurance side, private insurers assess named-patient imports case by case, but coverage for unregistered specialty drugs is uncommon. The realistic default is cash-pay.
Typical timeline for Praluent in Pakistan
We give you a written timeline estimate for your case before you commit. Reserve Meds plans logistics to a major-city dispensing facility and works with the family on the in-country last mile. Recurring fills on the 75 mg or 150 mg every-two-weeks regimen or the 300 mg monthly regimen run faster once the first fill is complete and the file is on record. Timelines are typical ranges, not promises.
What your physician needs to provide
The clinical justification letter for Praluent is the centerpiece of the DRAP package. For this product the letter typically includes:
- The confirmed indication: adult HeFH, adult HoFH (as adjunct to other LDL-lowering therapies), adult ASCVD requiring additional LDL-C lowering, or adult cardiovascular risk reduction after acute coronary syndrome
- For FH cases: genetic testing report identifying the pathogenic variant, or clinical-diagnostic criteria documentation (Dutch Lipid Clinic Network or Simon Broome).
- Lipid-panel history documenting LDL-C trajectory on maximally tolerated statin therapy with or without ezetimibe, including the response inadequacy that justifies adding a PCSK9 inhibitor
- For ASCVD post-ACS cases: documentation of the qualifying acute coronary syndrome event
- The dosing schedule chosen: 75 mg subcutaneously every 2 weeks, 300 mg subcutaneously every 4 weeks, or 150 mg subcutaneously every 2 weeks; for HoFH cases or HeFH patients undergoing LDL apheresis, 150 mg every 2 weeks
- The monitoring plan: LDL-C measurement 4 to 8 weeks after initiation or dose change to assess response and inform any dose adjustment; injection-site reaction surveillance; vigilance for hypersensitivity reactions; no routine hepatic or hematologic monitoring is required by the label
The treating physician's PMDC license verification anchors the application. Cardiologists, lipidologists, pediatric cardiologists, and internal medicine physicians with lipid-clinic experience at the major tertiary centers all have signing authority on Personal Use Import clinical justification letters.
Common questions about Praluent in Pakistan
Will a private insurer cover Praluent? Coverage for named-patient imports of specialty biologics is uncommon across Pakistani health plans. Some plans pay a partial percentage on a case-by-case basis where the drug is on a global formulary equivalent. We supply the documentation the insurer needs to assess the claim; the claim itself is yours or your hospital's to file. The realistic default is cash-pay.
How does family cascade screening for FH help my application? Cascade screening of first-degree relatives in known FH families can identify affected relatives. If your family has been identified through cascade screening, the cascade-pedigree documentation strengthens the clinical justification letter materially, particularly for pediatric or young-adult cases where genetic confirmation is in progress.
Our family pools funds across Pakistan, the Gulf, and the UK. How does Reserve Meds handle that? Pakistan's diaspora remittance pattern is well-established, and many families consolidate funds across overseas relatives before treatment can start. The transparent written quote on the firm-quote document lets you plan funding before contacting us.
Is there a competitor or alternative? The principal class competitor is evolocumab (Repatha), an Amgen PCSK9 monoclonal antibody with a similar mechanism and outcomes profile (FOURIER trial for Repatha, ODYSSEY OUTCOMES for Praluent). Inclisiran (Leqvio, Novartis), a small interfering RNA therapy targeting PCSK9 mRNA, offers a twice-yearly dosing alternative after initial loading. Reserve Meds does not promote one over the other; the named-patient pathway supports either based on the prescription written.
Can Praluent be self-administered at home? Yes. The 75 mg and 150 mg pre-filled pens, and the 300 mg presentation, are designed for patient or caregiver self-administration into the thigh, abdomen, or upper arm with site rotation between injections. We coordinate injection training with your prescriber prior to first shipment. The dispensing facility must still be Pakistani-licensed; the carton is handed to the patient from the hospital pharmacy or specialty importer pharmacy, and the patient administers at home.
What is the safety profile? The most common adverse reactions in clinical trials were injection-site reactions, nasopharyngitis, and influenza-like symptoms. Hypersensitivity reactions have been reported, including rare cases requiring discontinuation. The product carries no boxed warning.
Where Reserve Meds fits in Praluent cases
Reserve Meds is a US-based digital health company. We do not replace your cardiologist or lipidologist, do not replace DRAP, and do not replace the dispensing hospital pharmacy or the in-country importer. For Praluent specifically we orchestrate supply through a US-licensed pharmaceutical wholesale partner with biologic export capability, prepare the regulatory documentation kit your physician needs for the DRAP Personal Use Import filing through OIES (FH or ASCVD indication letter template, lipid-panel summary, dosing schedule, monitoring plan, cascade-screening documentation where available), coordinate the international 2 to 8 degree Celsius cold-chain logistics with continuous temperature monitoring and data-logger inclusion to Karachi, Lahore, or Islamabad, and run a single point of contact throughout the case in English and Urdu. We do not coordinate off-label use. For FH families pursuing chronic therapy over years, we structure recurring fill cadence so the next shipment is on its way before the current carton runs out.
Next step
If your cardiologist or lipidologist has decided Praluent is the right next step for your FH or ASCVD case and local stocking or pricing is the bottleneck, the named-patient pathway through DRAP is the route.
Reserved for you.